Vestmark Advisory Solutions Inc. Sells 339 Shares of Boston Scientific Co. (NYSE:BSX)

Vestmark Advisory Solutions Inc. lowered its position in Boston Scientific Co. (NYSE:BSX) by 0.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 38,977 shares of the medical equipment provider’s stock after selling 339 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Boston Scientific were worth $2,253,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in BSX. Bruce G. Allen Investments LLC bought a new stake in Boston Scientific during the 4th quarter valued at $28,000. Venturi Wealth Management LLC raised its holdings in shares of Boston Scientific by 58.0% in the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 215 shares during the last quarter. Motco lifted its position in Boston Scientific by 136.3% in the 3rd quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 372 shares in the last quarter. Cetera Trust Company N.A acquired a new position in Boston Scientific during the 4th quarter valued at about $43,000. Finally, Asset Dedication LLC increased its holdings in Boston Scientific by 42.6% during the 3rd quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 235 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, CFO Daniel J. Brennan sold 13,662 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares in the company, valued at $3,779,820.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the sale, the chief financial officer now owns 271,542 shares of the company’s stock, valued at $17,883,756.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 78,384 shares of company stock valued at $5,395,560. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $0.82 during trading on Friday, hitting $72.85. 7,452,084 shares of the company were exchanged, compared to its average volume of 7,241,391. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $74.39. The stock has a 50 day moving average of $68.42 and a 200 day moving average of $61.27. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 0.82. The company has a market cap of $106.88 billion, a PE ratio of 61.22, a P/E/G ratio of 2.51 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The business had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. During the same quarter last year, the company earned $0.45 EPS. As a group, equities research analysts predict that Boston Scientific Co. will post 2.32 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BSX. JPMorgan Chase & Co. lifted their target price on Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a research note on Thursday, April 25th. Barclays raised their price target on shares of Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. Needham & Company LLC upped their price objective on shares of Boston Scientific from $71.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, Evercore ISI lifted their target price on shares of Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $75.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.